Put companies on watchlist
SCHOTT Pharma AG & Co. KGaA
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Curious about what AI knows about SCHOTT Pharma? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

SCHOTT Pharma AG & Co. KGaA · ISIN: DE000A3ENQ51 · EQS - adhoc news (34 News)
Country: Germany · Primary market: Germany · EQS NID: 2179338
05 August 2025 09:53AM

SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin


EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin

05-Aug-2025 / 09:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
SCHOTT Pharma specifies FY 2025 guidance:
  • Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management expectations between 6.0% and 9.0% (“high-single digit”).
  • The EBITDA margin for FY 2025 is expected to be around 28.0%, above the previous guidance of “approximately at the level of FY 2024 (26.9%)”.
The above specification is based on preliminary results in the first nine months and the outlook for the full fiscal year 2025.

For further information and preliminary Q3/9M 2025 financial results we refer to our supplemental press release.

The full set of Q3/9M 2025 financial results will be published on August 12, 2025.

Contact
Lea Kaiser 
PR & Communications Manager 
Tel.: +49 (0) 151 68917195 
E-Mail: lea.kaiser@schott.com 
 
Tobias Erfurth 
Head of Investor Relations 
E-Mail: ir.pharma@schott.com 
 
Jasko Terzic, CFA 
Senior Manager Investor Relations 
E-Mail: ir.pharma@schott.com 

 


End of Inside Information

05-Aug-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2179338

 
End of Announcement EQS News Service

2179338  05-Aug-2025 CET/CEST

Visual performance / price development - SCHOTT Pharma AG & Co. KGaA
Smart analysis and research tools can be found here.
MIC: XETR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.